The primary goal of this study is to test the hypothesis that oral nabilone treatment will
reduce agitation compared with placebo in patients with Frontotemporal Dementia (both
behavioural variant frontotemporal dementia and primary progressive aphasia). The study
population is defined as patients with probable Frontotemporal Dementia that meet the
International Psychogeriatric Association criteria for agitation in cognitive disorders.